IRONWOOD PHARMACEUTICALS, INC. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- IRONWOOD PHARMACEUTICALS, INC. payments for repurchase of common stock for the quarter ending 2022-12-31 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. payments for repurchase of common stock for the quarter ending 2022-09-30 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. payments for repurchase of common stock for the quarter ending 2022-06-30 was $33.90M.
- IRONWOOD PHARMACEUTICALS, INC. payments for repurchase of common stock for the quarter ending 2022-03-31 was $92.50M.
- IRONWOOD PHARMACEUTICALS, INC. payments for repurchase of common stock for fiscal 2022 was $126.39M, a 423.78% increase from fiscal 2021.
- IRONWOOD PHARMACEUTICALS, INC. payments for repurchase of common stock for fiscal 2021 was $24.13M.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $126.39M 10-K · filed 2025-03-31 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | |
| 2022-06-30 | $33.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | |
| 2022-03-31 | $92.50M 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $24.13M 10-K · filed 2024-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |